Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Izzo, Nicholas J ^a   Xu, Jinbin ^b   Zeng, Chenbo ^b   Kirk, Molly J ^e,i   Mozzoni, Kelsie ^a   Silky, Colleen ^a   Rehak, Courtney ^a   Yurko, Raymond ^a   Look, Gary ^a   Rishton, Gilbert ^a   Safferstein, Hank ^a   Cruchaga, Carlos ^f   Goate, Alison ^f   Cahill, Michael A ^j   Arancio, Ottavio ^g   Mach, Robert H ^b   Craven, Rolf ^d   Head, Elizabeth ^d   LeVine, Harry ^c   Spires Jones, Tara L ^e,h   Catalano, Susan M ^a   more..

^a From Cognition Therapeutics Inc   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ NORTHEASTERN UNIVERSITY   (United States)

^j CHARLES STURT UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CT 0093; CT 0109; CT 01344; CT 01346; OLIGOMER; OPIATE ANTAGONIST; PROGESTERONE RECEPTOR; PROTEIN PGRMC1; SIGMA 2 OPIATE RECEPTOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PGRMC1 PROTEIN, MOUSE; PROTEIN BINDING; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE TRANSPORT; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SYNAPSE; SYNAPTOTOXICITY; UPREGULATION; ANIMAL; AUTORADIOGRAPHY; BRAIN; CELL MEMBRANE; CHEMISTRY; COGNITION; COGNITION DISORDERS; DRUG EFFECTS; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; BRAIN; CELL MEMBRANE; COGNITION; COGNITION DISORDERS; HUMANS; MEMBRANE PROTEINS; MICE; NEURONS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROGESTERONE; RNA, SMALL INTERFERING; SYNAPSES;

EID: 84911468890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111899     Document Type: Article

References (60)

1. Klein WL, Krafft G, Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum. Trends Neurosci 24: 219-224.
2. Mucke L, Selkoe DJ (2012) Neurotoxicity of Amyloid beta-Protein: Synaptic and Network Dysfunction. Cold Spring Harb Perspect Med 2: a006338.
3. Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, et al. (2012) Different beta-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 33: 825 e821- 813.
4. Haes AJ, Chang L, Klein WL, Van Duyne RP (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127: 2264-2271.
5. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358.
6. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, et al. (2013) Amyloidbeta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73: 104-119.
7. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, et al. (2013) New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement 9: 99-112.
8. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT (2013) A Luminex assay detects amyloid beta oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One 8: e67898.
9. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, et al. (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79: 887-902.
10. Kessels HW, Nabavi S, Malinow R (2013) Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A 110: 4033-4038.
11. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, et al. (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66: 739-754.
12. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, et al. (2013) Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136: 1383-1398.
13. Kam TI, Song S, Gwon Y, Park H, Yan JJ, et al. (2013) FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest 123: 2791-2802.
14. Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, et al. (2012) Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51: 95-106.
15. Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, et al. (2013) Amyloidbeta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32: 2920-2937.
16. Zempel H, Mandelkow EM (2012) Linking amyloid-beta and tau: amyloid-beta induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. Neurodegener Dis 10: 64-72.
17. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24: 10191-10200.
18. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52: 831-843.
19. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796-807.
20. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, et al. (2006) Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33: 274-282.
21. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005)n Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
22. Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, et al. (2011) Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging 32: 614-623.
23. Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, et al. (2006) The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 6: 597-608.
24. Marcello E, Epis R, Di Luca M (2008) Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. Eur - J Pharmacol 585: 109-118.
25. Viola KL, Velasco PT, Klein WL (2008) Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 12: 51S-57S.
26. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, et al. (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36: 293-302.
27. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, et al. (2013) Human LilrB2 Is a b-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer's Model. Science 341: 1399-1404.
28. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, et al. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469: 47-52.
29. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128-1132.
30. Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, et al. (2014) Alzheimer's therapeutics targeting Amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS ONE 10: e0111898.
31. Leonard BE (2004) Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 37 Suppl 3: S166-170.
32. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, et al. (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2: 380.
33. Rohe HJ, Ahmed IS, Twist KE, Craven RJ (2009) PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther 121: 14-19.
34. Cahill MA (2007) Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 105: 16-36.
35. Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, Weinandy F, Waidelich M, et al. (2007) Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 6: 283-293.
36. Mir SU, Ahmed IS, Arnold S, Craven RJ (2012) Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 131: E1-9.
37. Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41: 345-352.
38. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79: 595-605.
39. Ganapathy ME, Prasad PD, Huang W, Seth P, Leibach FH, et al. (1999) Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J Pharmacol Exp Ther 289: 251-260.
40. Sun J, Cairns NJ, Perlmutter JS, Mach RH, Xu J (2013) Regulation of dopamine D receptor in the striatal regions and substantia nigra in diffuse Lewy body disease. Neuroscience 248C: 112-126.
41. McDonald JM, Cairns NJ, Taylor-Reinwald L, Holtzman D, Walsh DM (2012) The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer's disease brain. Brain Res 1450: 138-147.
42. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
43. Mishina M, Ohyama M, Ishii K, Kitamura S, Kimura Y, et al. (2008) Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 22: 151-156.
44. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, et al. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135: 2155-2168.
45. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, et al. (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106: 4012-4017.
46. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, et al. (2011) Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 14: 545-547.
47. Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, et al. (2012) Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer 106: 693-701.
48. Zeng C, Rothfuss JM, Zhang J, Vangveravong S, Chu W, et al. (2013) Functional assays to define agonists and antagonists of the sigma-2 receptor. Anal Biochem 448C: 68-74.
49. Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, et al. (2014) A sensitive abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. J Neurosci 34: 2884-2897.
50. Szczesna-Skorupa E, Kemper B (2011) Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol 79: 340-350.
51. Nolte I, Jeckel D, Wieland FT, Sohn K (2000) Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim Biophys Acta 1543: 123-130.
52. Vilner BJ, John CS, Bowen WD (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408-413.
53. Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349-357.
54. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, et al. (2000) Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 20: 1386-1392.
55. Hyman BT (2011) Caspase activation without apoptosis: insight into Abeta initiation of neurodegeneration. Nat Neurosci 14: 5-6.
56. Mir SU, Schwarze S, Jin L, Zhang J, Friend W, et al. (2013) Sigma-2 receptor associates with MAP1-LC3B and promotes autophagy.
57. Ahmed IS, Rohe HJ, Twist KE Craven RJ (2010) Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 285: 24775-24782.
58. Thomas P, Pang Y, Dong J (2014) Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRalpha) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology: en20131991.
59. Klein WL (2013) Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 33 Suppl 1: S49-65.
60. Selkoe DJ (2013) SnapShot: Pathobiology of Alzheimer's Disease. Cell 154: 468- 468 e461.